Eylea: intravitreal injection for macular degeneration

Eylea (aflibercept) is licensed for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Following an initial treatment schedule of monthly injections for 3 months, aflibercept may be administered at two-monthly intervals thus reducing the risks associated with intravitreal administration
Following an initial treatment schedule of monthly injections for 3 months, aflibercept may be administered at two-monthly intervals thus reducing the risks associated with intravitreal administration

PHARMACOLOGY

Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) receptors 1 and 2. By binding to these receptors, it inhibits the action of both VEGF-A and placental growth factor, thus reducing the abnormal growth of blood vessels that is associated with wet AMD.1

CLINICAL STUDIES

Two double-blind, parallel-group phase III studies (VIEW 1 and VIEW 2) compared aflibercept with ranibizumab in terms of safety and efficacy in patients with wet AMD.2

Investigators randomised patients (n=2,419) in a 1:1:1:1 ratio to receive the following treatments by intravitreal injection: aflibercept 500 microgram monthly; aflibercept 2mg monthly; aflibercept 2mg monthly for 3 months then every two months; or ranibizumab 500 microgram monthly.2

The primary endpoint was maintenance of vision, defined as losing fewer than 15 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.2

Non-inferior to ranibizumab

At week 52, all aflibercept groups in both trials met the 7% non-inferiority margin when compared with monthly ranibizumab for the primary endpoint in a pre-specified integrated analysis. Additionally, the aflibercept groups were within 0.5 letters of the ranibizumab group in terms of mean change in best corrected visual acuity in the combined analysis.2

Safety and tolerability

The safety profile of aflibercept was comparable to that of ranibizumab, with similar rates of both ocular and non-ocular adverse events.2

References:

  1. Eylea Summary of Product Characteristics, November 2012.2. Heier JS et al. Ophthalmology 2012; 119; 2537–48.
  2. Heier JS et al. Ophthalmology 2012; 119; 2537–48.

View Eylea drug record

Further information: Bayer plc

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in